Dear Doctor Letter (Rote-Hand-Brief) on Lynparza® (olaparib): risk of medication errors due to new dosage forms
2018.05.29
Active substance: olaparib
Lynparza® capsules and Lynparza® tablets must neither be substituted 1:1 nor on a milligramme-to-milligramme basis.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN